Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Experts discuss the importance of transitioning cancer care from academic centers to community settings, ensuring effective ...

A common care partner challenge is managing guilt when engaging in activities for personal wellness, especially if the multiple myeloma patient cannot participate.

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

STUDIO CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of Directors.

But we do have all these great treatments, and we're hoping that the overall survival of those patients will keep getting longer and longer, and maybe one day myeloma could be potentially cured. I ...

Hospitals are reporting significant success in treating multiple myeloma, with patients undergoing advanced therapies, ...

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...